The TRACK Trial

Improving cardiovascular health of patients with chronic kidney disease. The TRACK trial will evaluate whether a small dose of rivaroxaban, a blood-thinning medication, would reduce cardiovascular death or major cardiovascular events in patients with advanced stages of chronic kidney disease.

Leads

Professor Sunil Badve
Program Lead, Cardiometabolic Trials, Renal and Metabolic Program
Associate Professor Meg Jardine
Honorary Professorial Fellow, The George Institute for Global Health
Professor Martin Gallagher
Director, Renal & Metabolic Division

The TRACK Trial

Leads

Professor Sunil Badve

Associate Professor Meg Jardine

Professor Martin Gallagher

The George Institute for Global Health

The George Institute country sites:

Acknowledgement of Country

The TRACK Trial

Leads

Professor Sunil Badve

Associate Professor Meg Jardine

Professor Martin Gallagher

Related projects

Treatment of cardiovascular disease with low dose Rivaroxaban in Advanced Chronic Kidney Disease (TRACK)